ATM and breast cancer: Nevertheless, the prognostic impact of ATM mutations seems to be limited in the analysis of TCGA datasets including BC patients (Supplementary Figure 4e), and the majority of BC patients (86%: 345 out of 401) had no mutation in ATM, which implies the importance of intact ATM as a therapeutic target.